These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38226446)

  • 21. Empagliflozin in the treatment of heart failure.
    Shafiq A; Hameed I; Biegus J; Fudim M; Khan MS
    Future Cardiol; 2024 Apr; 20(5-6):251-261. PubMed ID: 38865086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA Expands Empagliflozin Heart Failure Indication.
    Larkin HD
    JAMA; 2022 Apr; 327(13):1219. PubMed ID: 35380600
    [No Abstract]   [Full Text] [Related]  

  • 27. Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.
    Shiraki A; Oyama JI; Shimizu T; Nakajima T; Yokota T; Node K
    Eur J Pharmacol; 2022 Sep; 931():175194. PubMed ID: 35987253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N
    Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
    Beusekamp JC; Tromp J; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P
    Eur J Heart Fail; 2021 Jun; 23(6):1049-1052. PubMed ID: 33899306
    [No Abstract]   [Full Text] [Related]  

  • 30. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC; Koch B; Freitag J; Schubert R; Geiger H
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Brueckmann M; Jamal W; Zeller C; Schnaidt S; Zannad F
    Circulation; 2021 Jan; 143(4):326-336. PubMed ID: 33081531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
    Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
    Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium glucose co-transporter 2 inhibitors in heart failure therapy.
    Çavuşoğlu Y; Altay H; Cahn A; Celik A; Demir S; Kılıçaslan B; Nalbantgil S; Raz I; Temizhan A; Yıldırımtürk Ö; Yılmaz MB
    Turk Kardiyol Dern Ars; 2020 Apr; 48(3):330-354. PubMed ID: 32281958
    [No Abstract]   [Full Text] [Related]  

  • 38. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
    Kräker K; Herse F; Golic M; Reichhart N; Crespo-Garcia S; Strauß O; Grune J; Kintscher U; Ebrahim M; Bader M; Alenina N; Heuser A; Luft FC; Müller DN; Dechend R; Haase N
    Sci Rep; 2020 Aug; 10(1):14061. PubMed ID: 32820187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.